Bicycle Therapeutics announces £20M ($32M) million financing for drug development

Cambridge, UK. Bicycle Therapeutics, a next generation biotherapeutics company developing first-in-class bicyclic peptides, today announced that it had secured an equity financing of £20 ($32M) million for the clinical development of therapeutic Bicycle drug candidates in oncology. The existing investor syndicate, Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences and Astellas Venture Management participated in the round. Read More